Antonio Antón-Torres

5PUBLICATIONS
65CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Implementation science and evaluation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Jul 09, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil

|Apr 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.

Antonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló

|Dec 20, 2022
Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.

Paula González Villarroel, Josep Gumà Padró, Gloria Marquina

|Feb 23, 2021
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications.

Carlos Camps, Rafael López, Antonio Antón

Pageof 1

Frequent Collaborators

3 joint publications

Manuel Ruiz-Borrego

2 joint publications

Carlos Camps

2 joint publications

Rafael López-López

2 joint publications

Miguel Martín